Table 2.
Analysis of Hospitalization as a Function of Hypoglycemic Therapy
| OR | 95% C.I. Lower Limit | 95% C.I. Upper Limit | P value | |
|---|---|---|---|---|
| Sex (M vs F) | 1.81 | 1.42 | 2.29 | <0.01 |
| Age Class (ref 18–49) | ||||
| 50–59 | 3.55 | 1.60 | 7.91 | <0.01 |
| 60–69 | 3.92 | 1.80 | 8.57 | <0.01 |
| 70–79 | 5.53 | 2.52 | 12.12 | <0.01 |
| Over 80 | 9.98 | 4.52 | 22.04 | <0.01 |
| Insulin | 1.48 | 1.15 | 1.92 | <0.01 |
| Metformin | 0.85 | 0.64 | 1.12 | 0.25 |
| Sulphonylureas/Glinides | 1.34 | 1.04 | 1.73 | 0.02 |
| Acarbose/Pioglitazone | 1.12 | 0.66 | 1.91 | 0.68 |
| DPP4i | 1.02 | 0.76 | 1.36 | 0.90 |
| GLP-1 RA | 1.09 | 0.75 | 1.58 | 0.65 |
| SGLT2i | 0.89 | 0.62 | 1.29 | 0.54 |
| Hypertension | 1.11 | 0.83 | 1.49 | 0.47 |
| Dyslipidemia | 0.98 | 0.77 | 1.25 | 0.88 |
| Other CV diseases | 1.23 | 0.95 | 1.58 | 0.12 |
| Renal faliure | 2.37 | 1.27 | 4.43 | 0.01 |
| Acquired immunodeficiencies | 1.41 | 0.76 | 2.61 | 0.28 |
| Cancer | 0.75 | 0.53 | 1.06 | 0.10 |
| Chronic respiratory diseases | 1.36 | 0.84 | 2.20 | 0.22 |
| Duration of diabetic disease | 0.99 | 0.97 | 1.01 | 0.30 |
Abbreviations: DPP4i, Dipeptidyl-Peptidase-4 inhibitors; GLP-1 RA, Glucagon-like peptide-1 receptor agonists; SGLT2i, Sodium-glucose cotransporter 2 inhibitors; CV, Cardiovascular.